Solid forms of 1-((S)-4-((R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one
AssigneeGenentech, Inc.
InventorAntonio Giovanni DIPASQUALE
Life of this patent
Estimating the term…
Abstract
Provided herein are salts and solid forms of 1-((S)-4-((R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one, including adipate, fumarate, ethylenesulphonate, besylate, and mesylate salts thereof.
Claims25
-53. (canceled)
A method of treating a cancer comprising a KRasG12C mutation in a patient having said cancer, the method comprising administering an effective amount of a crystal form comprising Compound A, Form A:
- having an X-ray powder diffraction pattern comprising characteristic X-ray powder diffraction peaks using CuKα radiation at 9.6474, 11.0365, 15.4059, 16.4193, and 18.7038 (±0.1°2θ).
A method of treating a cancer comprising a KRasG12C mutation in a patient having said cancer, the method comprising administering an effective amount of a crystal form comprising Compound A, Form B:
- having an X-ray powder diffraction pattern comprising characteristic X-ray powder diffraction peaks using CuKα radiation at 5.2063, 14.63, 17.7161, 21.9253, and 25.1335 (±0.1°2θ).
A method of treating a cancer comprising a KRasG12C mutation in a patient having said cancer, the method comprising administering an effective amount of a crystal form comprising Compound A, Form D:
- having an X-ray powder diffraction pattern comprising characteristic X-ray powder diffraction peaks using CuKα radiation at 9.7745, 11.0487, 15.2452, 18.6477, and 18.7908 (±0.1°2θ).
Dependencies are inferred from the claim text.